Abstract
Introduction
Breast cancer is a heterogeneous disease usually composed of four molecular subtypes including luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC) [1] . TNBC is defined by negative of expression of the ER, PR, and HER2 amplification, accounting for approximately 15% of all breast cancers. Despite major advances in ER-positive or HER2--amplified breast cancers, there is no targeted agent currently available for TNBC, leaving cytotoxic chemotherapy as the only option for systemic therapy [2] . In addition, TNBC is more aggressive than other breast cancer subtypes for its propensity for recurrence and metastasis, causing that the prognosis for TNBC patients is very poor [3] . Therefore, it is urgent to identify new potential therapeutic targets for TNBC.
The high-throughput technologies allow simultaneous examination of the global gene expression, and have been used in many fields. The application of these technologies could categorize the characteristics of different subtypes of cancers, and identify genes that may be used as novel molecular targets for therapeutic modalities [4] . Gene expression profiling has stratified breast cancer into discrete biologic subtypes that largely associated with the expression status of ER, PR, and Her2 in tumor cells [5] , contributing to the molecular biology of the disease in a subtype specific manner. Xi Chen et al. discovered six TNBC subtypes from 587 TNBC samples based on gene expression patterns, developing a subtyping tool for TNBC [6] . Komatsu et al. performed microarray analysis on 30 TNBC and 13 normal epithelial ductal cells, identified differentially expressed genes (DEGs) involved in cell cycle such as ASPM and CENPK which mediated the cell viability of TNBC [7] . Recently a integrated analysis has been conducted in the Oncomine database to identify 206 deregulated genes [8] in TNBC compared with non-TNBC and these genes was also found to be deregulated in tumors that metastasized or led to death within 5 years, enriching in two core biological functions: CIN and ER signaling. In this integrated analysis the heterogeneity was increased due to clinical samples experiencing different chemotherapy among multiple datasets. However in our integrated analysis, we first used microarray analysis to identify differentially expressed genes (DEGs) and biological processes associated with TNBC. Furthermore we aim to back up our result by conducting a integrated analysis of our own and published gene expression data of TNBC in breast tissues without drug treatment, leading to more robust, reproducible and accurate predictions [9] . To verify the findings in the integrated analysis, some genes were selected to perform qRT-PCR in breast cancer cell lines. Our study adds a novel insight into the understanding of pathological mechanism underlying breast cancers. In addition, it would help to identify putative therapeutic targets in treating different subtypes of breast cancer.
Materials and Methods

Patients and tissues
The breast tissues of different breast cancer subtypes (including 2 samples of TNBC, 1 sample of LuminalA, 1 sample of LuminalB and 4 samples of HER2+) were provided by the Second People's Hospital of Shenzhen, with the approval of patients and hospital authorities. All protocols were approved by the Second People's Hospital of Shenzhen Medical Ethics Committee. The written informed consent forms were obtained from patients or legal guardians of the patients. Clinical information of the patients was abstracted from medical records and they were diagnosed as triple-negative by pathologists with immunohistochemical staining showing ERnegative, PR-negative, and HER2 (0 or 1+). The tissues were obtained from biopsies and stored in 1ml RNAlater solution.
Microarray analysis
RNA extracted using the Qiagen RNeasy kit according to the manufacturer instructions. Human HT expression beadchip V4 array (illumina) was performed to detect gene expression profiles of breast cancer samples. GenomeStudio (Illumina) was used to process and analyze raw signal intensities of gene expression data, with background correction, quantile normalization conducted on the average signal intensities. P-value was computed. Fold changes in gene expression, which is the ratio of average expression level between TNBC and non-TNBC group, were calculated. The Illumina customer model employed multiple testing corrections to compute the false discovery rate (FDR). Differentially expressed genes (DEGs) between TNBC and non-TNBC samples were subsequently determined. Heat map analysis was conducted using the "heatmap.2" function of the R/Bioconductor package "gplots" [10] .
Integrated analysis of microarray datasets
To obtain maximal information regarding the difference of gene expression profiling between TNBC and non-TNBC in the present study, integrated analysis was performed combining the microarray data presented here together with all previous microarray data. To this end, we searched the Gene Expression Omnibus database (GEO, http://www.ncbi.nlm.nih.gov/geo) [11] with keywords "triple-negative breast cancer, gene expression, microarray, genetics". We only selected the original experimental microarray studies that analyzed gene expression profiling of breast tumor tissues between TNBC and non-TNBC in human. Expression profiles obtained by integrated analysis or with other treatment were excluded.
Different gene IDs or probe IDs was uniformly converted to Entrez IDs. Intensity values of each probe-set were log2 transformed, and Z-score were calculated to incorporate betweenstudy heterogeneities across multiple studies [12] . A gene specific t-test was carried out between TNBC and non-TNBC, then p-value and effect size of each microarray study were calculated. P-value from multiple studies was combined using Fisher test, and the random effects model was used to combine effect size from multiple studies. We selected genes with combined p-value < 0.01 and the absolute value of combined ES > 1 as DEGs.
Functional annotation of DEGs
Gene Ontology (GO) enrichment analysis was carried out to uncover the biological functions of the DEGs. Additionally, the biological pathway enrichment analysis of all DEGs was performed based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. The online based software GENECODIS, a function analysis tool, which integrated kinds of information resources (GO, KEGG or SwissProt) was available to perform these analyses [13] .
PPI Network Construction
The protein-protein interactions (PPIs) analysis could visualize functional links between DEGs and other genes at the molecular level [14] , which is useful to help understand the molecular mechanism of diseases and its potentially essential genes. In our present study, PPI network of the top 10 up-and down-regulated DEGs was established based on Biological General Repository for Interaction Datasets (BioGRID) (http://thebiogrid.org/), and visualized with Cytoscape software [15] to find the hub proteins of the network.
QRT-PCR validation
The total RNA from each sample was extracted using Trizol method (BeijingDingGuoChangSheng Biotechnology Co., Ltd.). Primer 5.0 software (PREMIER Biosoft, Palo Alto, CA) was utilized to design primers for SYBR-Green experiments based on template sequences, and an ABI 7500 Real Time PCR System (Applied Biosystems, Carlsbad CA) was used. For each replicate, cDNA was synthesized from 1-5 μg RNA using Superscript Reverse Transcriptase II (TOYOBO). The qRT-PCR reaction consisted of 12.5 μl of Power SYBR Green PCR Master Mix (Applied Biosystems/Life Technologies, Carlsbad, CA), 1 μl diluted cDNA and 0.25 μl of each primer (10μM)) contributing a total volume of 25 μl. Reactions were conducted in triplicate, and run in 96-well plates as the following conditions: 94°C for 2 min, 35 cycles of 94°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec, and 72°C for 10 min. Relative gene expression was analyzed using Data Assist Software version 3.0 (Applied Biosystems/Life Technologies), using human GAPDH gene as endogenous controls for RNA load and gene expression in analysis.
Result
Microarray analysis
We selected 8 cases of breast cancers including 2 cases of TNBC and 6 cases of non-TNBC, which were identified by immuno-histochemical staining of ER, PR and HER2. The clinical and pathological features of the samples are summarized in Table 1 . To delineate the changes in gene expression patterns between TNBC and non-TNBC, we performed microarray analysis. The DEGs with p < 0.003 were identified and displayed in a heat map across different subtypes of breast cancers (Fig 1) .
DEGs in the integrated analysis of microarray datasets
After electronic search, only two microarray studies were obtained according to the inclusion criteria (S1 Table) . We subsequently combined these microarray studies to our own data to perform an integrated analysis which it contained 30 samples of TNBC and 77 samples of non-TNBC. The individual studies for integrated analysis were displayed in Table 2 . The integrated analysis showed that a total of 556 genes were found to be consistently differentially expressed with 344 genes up-regulated and 212 genes down-regulated in TNBC (S2 Table) . The top 10 most significantly up-or down-regulated genes were listed in Table 3 . COL4A2 (collagen, type IV, alpha 2), the most significantly up-regulated gene (p-value = 1.46E-10), encodes one of major structural components of basement membranes. Previous studies found that COL4A2 was significantly overexpressed in ER-positive breast cancer compared to ER-negative breast cancer [16] . CMBL (carboxymethylenebutenolidase homolog (Pseudomonas)), as a cysteine hydrolase of the dienelactone hydrolase family, was found to be the most significant down-regulated gene (p = 4.29E-09).
Functional annotation
GO enrichment analysis of DEGs was performed to understand their biological functions. GO categories are separated into 3groups: molecular function, biological process and cellular component. In our analysis, the 3 categories were detected respectively using web-based software GENECODIS. We found that the significantly enriched GO terms for molecular functions were protein binding (GO: 0005515, p = 6.09E-21) and nucleotide binding (GO: 0000166, p = 7.47E-08), while those for biological processes were signal transduction (GO:0007165, p = 9.46E-08) and positive regulation of transcription from RNA polymerase II promoter (GO: 0045944, p = 5.41E-06) and those for cellular component were cytoplasm (GO: 0005737, p = 2.09E-21) and nucleus (GO: 0005634, p = 1.38E-17) (Fig 2) . The pathway enrichment analysis was also conducted to further evaluate the biological pathways the DEGs involved. Hypergeometric test was carried out with p-value < 0.05 as the criteria for significant pathway identification (Table 4 ). The most significantly enriched pathway was Pathways in cancer (p = 6.54E-05). Furthermore, Jak-STAT signaling pathway (p = 4.35E-04) and Osteoclast differentiation (p = 5.62E-04) were found to be significantly enriched.
PPI network construction
The PPI networks of the top 20 most significantly dysregulated genes were established including 221 nodes, 160 edges. The significant hub proteins contained DUSP1 (dual specificity phosphatase 1, Degree = 21), MYEOV2 (myeloma overexpressed 2, Degree = 15) and UQCRQ (ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kDa, Degree = 14) (Fig 3) . In addition we labeled the edges connecting top 20 most significantly dysregulated genes directly or indirectly with numbers in Fig 3 and provided annotation in S3 Table. 
QRT-PCR validation
To validate the findings in the integrated analysis, we selected 5 genes (COL4A2, BMF, DUSP1, FOXA1, MLPH) of the top 10 up or down regulated genes to perform qRT-PCR in 
Discussion
The molecular signatures of breast cancer subtypes not only reflect the biological features of the corresponding malignant neoplasms, but also predict their clinical behavior and responses to given therapy, with some subtypes having better outcomes than others [17, 18] . In this paper, gene expression analysis was performed by microarray to compare gene expression profiling of TNBC to that of non-TNBC, followed by integrated analysis of our own and published expression data to identify key genes and biological pathways directing the development of effective targeted therapies for TNBC. In total, 556 genes (344 genes up-regulated and 212 genes downregulated in TNBC) were consistently expressed differentially between TNBC and non-TNBC in the integrated analysis. COL4A2 was the most significant up-regulated gene in this integrated analysis, and this high expression in TNBC was further confirmed by qRT-PCR. COL4A2 was also found to be significantly overexpressed in ER-negative breast cancer compared with ER-positive breast cancer [16] , which was in line with our finding. Among the top 10 up-regulated DEGs, BMF (BCL2-modifying factor), which interacts with prosurvival Bcl-2 family members to trigger apoptosis [19] , was down-regulated in MCF-7 breast cancer cells as a consequence of induced NeuT overexpression [20] . In qRT-PCR result, the expression of BMF in MCF-7 breast cancer cells was also lower than the other breast cancer cell lines. The role of BMF on the development of TNBC was unknown. CMBL (carboxymethylenebutenolidase homolog (Pseudomonas)), the most significant down-regulated gene, was found to be highly expressed in liver cytosol, but the association with breast cancer wasn't reported. In our study, several genes of the top 10 down-regulated DEGs such as DUSP1, FOXA1, MLPH was implicated in the development of breast cancer. DUSP1 (also known as MKP-1), a member of the dual-specificity phosphatases (DUSPs) which interacted and catalyzed dephosphorylation of active MAPK, mediated anti-proliferative and anti-inflammatory actions of PR in the breast cancer [21] . In this study, we found that the expression of DUSP1 was lower in TNBC than that in non-TNBC by integrated analysis and qRT-PCR, and may be associated with ER status. Furthermore our results of PPI network also detected the important role of DUSP1, which may be considered as a potential target gene for the treatment of TNBC. As a key determinant of estrogen receptor function and endocrine response [22] , FOXA1 participated with ERα and GATA3 in a complex transcriptional regulatory program to drive tumor growth [23] in estrogen receptor-α (ERα)-positive breast tumors, so the absence of estrogen receptor may lead to the decrease of FOXA1 expression. Our result indicated that FOXA1 expression was lower in TNBC as compared to non-TNBC. MLPH was found to be significantly over-expressed in ERα (+) breast tumors as compared to ERα (-) breast tumors [24] by microarray analysis and RT-qPCR confirmation, while this was not observed in our study, and the main reason may be utilization of different sample source and sample size.
Pathways in cancer and Jak-STAT signaling pathway were found to be highly enriched for the DEGs. Amounts of pathways were implicated in the development of breast cancer. Importantly, we noted that the most significantly enriched pathway was Pathways in cancer, which refers to some classical pathways such as Wnt signaling pathway, PI3K-Akt signaling pathway, Jak-STAT signaling pathway, MAPK signaling pathway, ErbB signaling pathway and some others together to regulate tumor growth and metastasis [25] . This finding further confirms that TNBC is more aggressive than other breast cancer subtype. Poage GM et al. suggested that the JAK/STAT was one of TNBC-specific regulatory feedback programs, and its critical signaling nodes could be used as the therapy target for the treatment of TNBC [26] .
In conclusion, by the integrated analysis and qRT-PCR validation, we showed the underlying molecular differences between TNBC and other breast cancer subtypes, and identified DEGs and biological function, which may help to understand the pathogenesis of different breast cancer subtypes and the development of drug therapy for TNBC. Further experiments in vivo and vitro are needed to uncover the biological function of the differentially regulated genes in the pathogenesis of TNBC.
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